FARMINGDALE, N.Y., Oct. 17, 2014 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, announces that it will host four Meet the Expert sessions at the Annual Meeting of the Congress of Neurological Surgeons "(CNS)" from October 20 to 22, 2014.

CNS plays an essential role in providing information on front-line technology and research to the neurosurgical community. CNS' annual meeting is generally attended by approximately 3,100 neurosurgeons and spine specialists each year.  "We are excited to be a part of this meeting and elated at the opportunity to show surgeons the value ultrasonic technology can add to surgery today and in the future," offered Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.

At its tradeshow booth (#1019), the Misonix team will be showcasing two of its ultrasonic therapeutic devices at this year's CNS meeting: the BoneScalpel System and the SonaStar® Aspiration System.

SonaStar provides precise and effective soft and hard tissue ablation with maximum control during neurosurgery and other various surgical specialties.

The Misonix BoneScalpel is an ultrasonic device providing surgeons with a bone cutting instrument that provides a clean, controlled bone incision and removal that is also soft tissue sparing.  The Meet the Expert sessions will be hosted at the Misonix booth at the annual CNS meeting and will focus on using the BoneScalpel in spine surgery. 

The sessions will be moderated by:

• Dr. Eric J. Woodard, New England Baptist Hospital, Boston, MA;
• Dr. Gregory Trost, University of Wisconsin, Madison, WI;
• Dr. Nicholas Renaldo, Vassar Brothers Medical Center, Poughkeepsie, NY; and
• Dr. Juan Uribe, University of South Florida, Tampa, FL.

Dr. Nicholas Renaldo explains, "This is a unique opportunity for neurosurgeons to learn how the BoneScalpel is being used in spine surgery today and the benefits it offers surgeons and patients."  He continues, "The BoneScalpel provides improved surgical efficiencies, reduced bleeding and soft tissue protection when incising bone and hard tissue during spinal procedures." 

Dr. Juan Uribe concurs, "I am honored to be a part of this learning series hosted by Misonix.  It gives me a chance to discuss my use of the BoneScalpel with fellow neurosurgeons and describe how I apply it in my minimally-invasive spine surgery procedures.  The BoneScalpel has become a valuable tool at my institution as it allows for controlled cutting of hard tissue and decrease blood loss while potentially avoiding soft tissue complications." 

All four Meet the Expert sessions are expected to be well attended and generate discussions on applying the BoneScalpel in a variety of spinal procedures.

Mr. McManus added, "We are excited to gather this renowned group of spine surgeons and avid BoneScalpel users to discuss, from a surgeon's perspective, their surgical experiences with the BoneScalpel and how it is making a difference in their practice."

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

SOURCE Misonix, Inc.